A Collaboration to Advance Hematology Research
There is a significant gap in the treatment for hematological diseases in China compared to other developed countries, according to Dr. Tao Cheng, scientific director and deputy president of the Institute of Hematology & Blood Diseases Hospital (IHBDH). “High-quality research based on real-world evidence can help us understand the reasons for this gap and improve the treatment of blood disease in China,” said Dr. Cheng.
To help address this situation, IHBDH, a clinical and research institute of the Chinese Academy of Medical Sciences and Peking Union Medical College, invited Analysis Group to partner with the institute to create the National Longitudinal Cohort of Hematological Diseases in China (NICHE), China’s first comprehensive blood disease research platform.
Analysis Group will work closely with IHBDH to design and build the platform, which will lay the foundation needed to evaluate treatment patterns, effectiveness, and safety; facilitate clinical decision making; and inform health policies and regulatory and reimbursement decisions.
The project will be designed to facilitate research on:
- Acute myeloid leukemia
- Lymphoma
- Multiple myeloma
- Hemophilia
- Pediatric hematological diseases
- Other blood diseases
“It is our aim to improve the survival rate and improve the quality of life of patients throughout China,” said Dr. Jianxiang Wang, medical director of IHBDH. “Making the right health care decisions that lead to improved patient outcomes requires being able to look at real-world evidence on relevant populations.”
Analysis Group will also assist IHBDH with assembling a scientific advisory committee drawn from experts in hematological diseases, health policy, health economics, epidemiology, biostatistics, bioinformatics, biotechnology, and biopharma. The committee will discuss and help address a range of important topics in the design, setup, and quality control of NICHE. ■
Additional information is available at www.niche-study.org.
